Joint involvement in inflammatory bowel disease: managing inflammation outside the digestive system

Area of Science:

• Rheumatology and Gastroenterology
• Immunology and Molecular Biology

Background:

• Approximately 30% of patients with inflammatory bowel disease (IBD) experience joint inflammation.
• Peripheral arthritis in IBD often responds to gut inflammation treatment and short-term NSAID use.
• Recurrent inflammation may necessitate sulfasalazine, while refractory cases and axial arthropathy often require anti-TNF biologics like infliximab and adalimumab.

Purpose of the Study:

• To explore the management of joint inflammation in inflammatory bowel disease.
• To investigate the underlying etiopathogenic mechanisms leading to varied disease phenotypes.
• To identify promising future therapeutic strategies for IBD-associated arthritis.

Main Methods:

• Review of current treatment strategies for IBD-associated arthritis.
• Discussion of the role of multidisciplinary approaches in research and clinical practice.
• Exploration of potential targets in animal models, including adhesion molecules, costimulatory molecules, and the Th17 pathway.

Main Results:

• Optimal management of gut inflammation is key for peripheral arthritis control.
• Sulfasalazine and anti-TNF agents (infliximab, adalimumab) are effective for recurrent or resistant arthritis and axial arthropathy.
• Multidisciplinary research is crucial for understanding shared etiopathogenic mechanisms and diverse disease phenotypes.

Conclusions:

• Effective management of IBD-associated joint inflammation involves a stepwise therapeutic approach.
• Further research into common etiopathogenic mechanisms and novel therapeutic targets is warranted.
• Animal models offer insights into future strategies like modulating adhesion molecules, costimulatory molecules, and the Th17 pathway.